Informazioni sul prodotto
RG7713 is an investigational drug that belongs to the class of cytochrome P450 3A4 (CYP3A4) inhibitors. RG7713 inhibits CYP3A4 activity and has been shown to be a potent inhibitor of CYP3A4-mediated metabolism in vitro. It is also a potent inhibitor of the human recombinant CYP3A4 enzyme, inhibiting the metabolic conversion of many drugs, including neuroleptics, antidepressants, antipsychotics, anticonvulsants, beta-blockers, and calcium channel blockers. RG7713 has demonstrated efficacy in preclinical studies in mice and rats for its cognition-enhancing effects. The drug was well tolerated at doses up to 10 mg/kg/day for 28 days without any adverse effects on body weight or food intake. There are no clinical studies yet on RG7713's safety and efficacy for humans.
Proprietà chimiche
Richiesta tecnica su: RG7713
Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine
